Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Evoke Pharma, Inc. EVOK
$1.96
-$0.09 (-4.39%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
6797464.00000000
-
week52high
5.96
-
week52low
1.37
-
Revenue
2508645
-
P/E TTM
-1
-
Beta
0.36955000
-
EPS
-2.83000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Neutral | 22 июн 2020 г. |
| H.C. Wainwright | Neutral | Buy | 05 мар 2019 г. |
| Seaport Global | Buy | 06 окт 2017 г. | |
| Laidlaw & Co. | Buy | Neutral | 30 янв 2017 г. |
| Rodman & Renshaw | Buy | Neutral | 05 янв 2017 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| WIDDER KENNETH J | A | 56000 | 56000 | 27 апр 2022 г. |
| REED VICKIE S | A | 58000 | 58000 | 27 апр 2022 г. |
| Hill Malcolm R | A | 57750 | 57750 | 27 апр 2022 г. |
| GARNER CAM L | A | 67500 | 67500 | 27 апр 2022 г. |
| Brady Todd C | A | 57750 | 57750 | 27 апр 2022 г. |
| D'Onofrio Matthew J | A | 100000 | 100000 | 02 февр 2022 г. |
| Gonyer David A | A | 175000 | 175000 | 02 февр 2022 г. |
| CARLSON MARILYN R. | A | 100000 | 100000 | 02 февр 2022 г. |
| REED VICKIE S | A | 70000 | 70000 | 13 мая 2021 г. |
| GARNER CAM L | A | 67500 | 67500 | 05 мая 2021 г. |
Новостная лента
Evoke Pharma, Inc. (EVOK) Q4 2022 Earnings Call Transcript
Seeking Alpha
21 мар 2023 г. в 18:39
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Gonyer - Chief Executive Officer Chris Quesenberry - GIMOTI's Chief Commercial Officer, EVERSANA Matthew D'Onofrio - Chief Business Officer Conference Call Participants Yale Jen - Laidlaw & Company Operator Good afternoon, and welcome to the Evoke Pharma's Fourth Quarter and Full Year 2022 Earnings Conference Call. Currently, all callers have been placed in listen-only mode, and following management's prepared remarks, the call will be opened for questions.
Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023
GlobeNewsWire
15 мар 2023 г. в 08:30
SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023, after the market closes.
Evoke Pharma, Inc. (EVOK) Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
09 ноя 2022 г. в 20:46
Evoke Pharma, Inc. (NASDAQ:EVOK ) Q3 2022 Results Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations, DKB Partners David Gonyer - President and Chief Executive Officer Chris Quesenberry - Chief Commercial Officer Matthew D'Onofrio - Executive Vice President, Chief Business Officer, Secretary and Treasurer Conference Call Participants Operator Good afternoon. And welcome to the Evoke Pharma Third Quarter 2022 Earnings Conference Call.
Evoke Pharma to Report Third Quarter Results on November 9, 2022
GlobeNewsWire
02 ноя 2022 г. в 08:30
SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its third quarter on Wednesday, November 9, 2022, after the market closes.
Evoke Pharma to Participate in H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
06 сент 2022 г. в 08:30
SOLANA BEACH, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced that the Company's President and CEO, David A. Gonyer, R.Ph., and Chief Business Officer, Matt D'Onofrio, MBA, will present at the H.C. Wainwright 24th Annual Global Investment Conference taking place from September 12-14, 2022, at the Lotte New York Palace Hotel in NYC.